Sara Velayati

Sara Velayati practices at Montefiore Einstein Advanced Care - HOPD in Elmsford, New York.

Sara Velayati's NPI, 1275095697, was assigned on April 4, 2019. Sara Velayati graduated from Mashhad University of Medical Sciences in 2011. Sara Velayati holds New York license 31789801.

Sara Velayati's primary practice is Montefiore Einstein Advanced Care - HOPD, at 555 Taxter Road, Elmsford, NY 10523.

Sara Velayati's primary practice is Montefiore Einstein Advanced Care - HOPD in Elmsford, New York. Sara Velayati is also affiliated with Montefiore Einstein Hospital-Moses Campus. The medical group on file is Montefiore Einstein Faculty Practice Group. Dmand AI also links Sara Velayati to 3 more medical groups, 2 group practices and clinics and 1 therapy and rehab clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Sara Velayati practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Sara Velayati's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Sara Velayati is licensed in New York.

CMS data shows 743 Medicare services from Sara Velayati across 5 procedure codes in 2024, for 337 Medicare patients. Medicare paid $65,389 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 337 Medicare patients who saw Sara Velayati in 2024. The largest group is 85 and over, with 125 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 30% are also on Medicaid. Their average risk score is 2.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Sara Velayati's median patient age at 67, with 53% women.

In 2024, Sara Velayati wrote 289 Medicare Part D claims for 116 patients. 88% of them were for generic drugs. CMS names the drug for 80 of them, across 5 drugs with 11 or more claims each, at $502 in total drug cost. In 2023, CMS named 87 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Sara Velayati for performance year 2024, reported as part of a group. CMS lists Sara Velayati as offering telehealth.

Dmand AI links 9 papers to Sara Velayati, published from 2019 to 2025. 2020 was the busiest year, with 2. The most frequent topics are Liver Neoplasms, Carcinoma, Hepatocellular and Embolization, Therapeutic. Sara Velayati has published most often in J Vasc Interv Radiol. Sara Velayati's most frequent co-authors are Lynn A. Brody, MD, Joseph Patrick Erinjeri, MD, PhD and William R. Jarnagin, MD.

CMS Open Payments shows 24 general payments to Sara Velayati from 8 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 97% of the total. Pfizer Inc. paid the most, $228.

Sara Velayati graduated from Mashhad University of Medical Sciences in 2011.